Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy

Summary

This is a prospective, randomized, multicenter, controlled trial. One hundred sixteen patients with primary membranous nephropathy (PMN) will be randomly divided into the intervention and control groups. The intervention group will be administered maximum tolerable dose of ACEI/ARB and finerenone 20 mg QD. Control patients will be administered maximum tolerable dose of ACEI/ARB. The primary endpoint is the relative change in urinary protein content from baseline to 6 months.

Timeline

Start

2024-09-30

Primary completion

2026-10-30

Completion

2026-10-30

Drugs

Indications